WHO Drug Information Vol. 18, No. 1, 2004
(2004; 109 pages) View the PDF document
Table of Contents
Open this folder and view contentsRegulatory Challenges
Close this folderEssential Medicines
View the documentTreating 3 million people living with HIV/AIDS by 2005
View the documentAIDS medicines and diagnostics service
View the documentFixed-dose combination therapy
View the documentHIV antiretrovirals and diagnostics funding
View the documentWorld Bank ARV procurement manual
View the documentResearch on new HIV microbicides
Open this folder and view contentsSafety and Efficacy Issues
Open this folder and view contentsVaccines and Biomedicines
Open this folder and view contentsHerbal Medicines
Open this folder and view contentsRegulatory and Safety Action
Open this folder and view contentsConsultation Document
View the documentProposed International Nonproprietary Names: List 90
View the documentRecommended International Nonproprietary Names: List 51
 

Research on new HIV microbicides

New antiviral agents are being developed by scientists and HIV experts from the UK Medical Research Council (MRC) and the Department for International Development (DFID). The antiviral properties of potential microbicides could work in a number of ways. They could kill or otherwise immobilize the virus, create a barrier to block infection, or prevent the infection from taking hold after it has entered the body. An effective microbicide would combine these mechanisms.

A large-scale trial is planned to evaluate the effectiveness of two of the six vaginal microbicides that are now in the final stages of clinical development. Updates on recent international microbicide research and development, including information on the first Phase III trials, will be released shortly.

Microbicides are likely to be of particular benefit to women who are increasingly bearing the brunt of the HIV epidemic and now account for over 50 per cent of people newly infected with HIV. Microbicides could potentially control the risk of contracting HIV and other sexually transmitted diseases.

Reference: http://www.mrc.ac.uk

 

to previous section to next section
 

Last updated: May 3, 2013